Currently Ongoing Studies definition

Currently Ongoing Studies means, collectively, the following clinical studies: (a) “Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia”; NCT01180426 [Recruiting], and (b) “Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (OPAL)”, NCT00780598 [Active, not recruiting], and (c) “A program of randomized phase II multicenter studies to assess the tolerability and
Currently Ongoing Studies means the following clinical studies: (i) [*]; and (ii) [*].
Currently Ongoing Studies means, collectively, the following clinical studies: (a) “Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia”; NCT01180426 [Recruiting], and (b) “Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (OPAL)”, NCT00780598 [Active, not recruiting], and (c) “A program of randomized phase II multicenter studies to assess the tolerability and efficacy of the addition of new drugs to standard induction chemotherapy in AML and RAEB > 66 years and very poor risk AML > 18 years”, Hovon 103, ▇▇▇▇-▇▇▇▇▇▇-▇▇ [Recruiting].

Examples of Currently Ongoing Studies in a sentence

  • The Parties intend and agree that any and all Currently Ongoing Studies shall be conducted by Chroma in consultation with the JDC, and in accordance with the Development Plan.

  • The Parties intend and agree that any and all Currently Ongoing Studies shall be conducted by Cell Genesys at its discretion, in collaboration and consultation with Takeda and in consultation with the JDC.

  • The Publication Team, established pursuant to Section 6.7(b), in close cooperation with the JDC will agree in advance on any publication of study results from the Currently Ongoing Studies, any Additional Studies, Licensed Territory Specific Studies or Extraterritorial Studies and prepare a joint publication strategy and publication plan, subject to the provisions of this Section 6.7.

  • Cell Genesys will provide all quantities of Product necessary to conduct the VITAL Studies, the Currently Ongoing Studies and any Additional Studies as may be required to perform such studies as and to the extent set forth in the Shared Territory Development Plan or the ROW Development Plan.

  • The Publication Team, established pursuant to Section 6.11(b), in close cooperation with the JDC and JCC will agree in advance on any publication of study results from the VITAL Studies, Currently Ongoing Studies, or Additional Studies and prepare a joint publication strategy and publication plan, subject to the provisions of this Section 6.11.

  • Cell Genesys will deliver such Product in accordance with current Distribution procedures until such time as Takeda has established and qualified Distribution capability and assumed responsibility for Distribution; thereafter, Cell Genesys will deliver such Product in accordance with the timeframes established by the parties through the JDC necessary to support the VITAL Studies, the Currently Ongoing Studies and any Additional Studies.

  • The general allocation of responsibilities for conducting Development of the Product shall be as follows: (1) Cell Genesys shall be responsible for performing the VITAL Studies and the Currently Ongoing Studies; and (2) except as provided in the following sentence, the JDC will allocate responsibility for the performance of any Additional Studies between the Parties.

  • In consultation with Takeda, Cell Genesys will be responsible for forecasting all quantities of Product to be used in connection with the VITAL Studies, Currently Ongoing Studies and any Additional Studies performed or monitored by Cell Genesys.

  • Cell Genesys agrees to register in the FDA clinical trial registry (▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇) the VITAL Studies, Currently Ongoing Studies, and any Additional Study conducted under an IND filed by Cell Genesys and as required by applicable Law.


More Definitions of Currently Ongoing Studies

Currently Ongoing Studies means, collectively, the following clinical studies: (a) “Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia”; NCT01180426 [Recruiting], and (b) “Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (OPAL)”, NCT00780598 [Active, not recruiting], and (c) “A program of randomized phase II multicenter studies to assess the tolerability and efficacy of the addition of new drugs to standard induction chemotherapy in AML and RAEB > 66 years and very poor risk AML > 18 years”, Hovon 103, 2009-014455-68 [Recruiting].